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Abstract
Background: Patients with 2009 pandemic influenza A(H1N1pdm09)-related critical illness were frequently treated
with systemic corticosteroids. While observational studies have reported significant corticosteroid-associated
mortality after adjusting for baseline differences in patients treated with corticosteroids or not, corticosteroids have
remained a common treatment in subsequent influenza outbreaks, including avian influenza A(H7N9). Our objective
was to describe the use of corticosteroids in these patients and investigate predictors of steroid prescription and
clinical outcomes, adjusting for both baseline and time-dependent factors.
Methods: In an observational cohort study of adults with H1N1pdm09-related critical illness from 51 Canadian ICUs,
we investigated predictors of steroid administration and outcomes of patients who received and those who did not
receive corticosteroids. We adjusted for potential baseline confounding using multivariate logistic regression and
propensity score analysis and adjusted for potential time-dependent confounding using marginal structural models.
Results: Among 607 patients, corticosteroids were administered to 280 patients (46.1 %) at a median daily dose of 227
(interquartile range, 154–443) mg of hydrocortisone equivalents for a median of 7.0 (4.0–13.0) days. Compared with
patients who did not receive corticosteroids, patients who received corticosteroids had higher hospital crude mortality
(25.5 % vs 16.4 %, p = 0.007) and fewer ventilator-free days at 28 days (12.5 ± 10.7 vs 15.7 ± 10.1, p < 0.001). The odds ratio
association between corticosteroid use and hospital mortality decreased from 1.85 (95 % confidence interval 1.12–3.04,
p = 0.02) with multivariate logistic regression, to 1.71 (1.05–2.78, p = 0.03) after adjustment for propensity score to receive
corticosteroids, to 1.52 (0.90–2.58, p = 0.12) after case-matching on propensity score, and to 0.96 (0.28–3.28, p = 0.95)
using marginal structural modeling to adjust for time-dependent between-group differences.
Conclusions: Corticosteroids were commonly prescribed for H1N1pdm09-related critical illness. Adjusting for only
baseline between-group differences suggested a significant increased risk of death associated with corticosteroids.
However, after adjusting for time-dependent differences, we found no significant association between corticosteroids
and mortality. These findings highlight the challenges and importance in adjusting for baseline and time-dependent
confounders when estimating clinical effects of treatments using observational studies.
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Background
During the 2009 influenza A(H1N1; (H1N1pdm09)
pandemic, the World Health Organization reported sub-
stantial influenza-related critical illness and mortality, es-
pecially among young people [1, 2], and H1N1pdm09 is
now among the most common seasonal influenza strains
[3]. Severe influenza-related critical illness typically mani-
fests as viral pneumonitis and acute respiratory distress
syndrome (ARDS). Despite available treatment options,
including admission to the intensive care units (ICUs),
neuraminidase inhibitors, and antibiotics for concomitant
or secondary bacterial infections, morbidity and mortality
remain high, with seasonal influenza currently estimated
to result in over 500,000 deaths globally each year [4–7].
Corticosteroids have long been used among critically ill
patients with ARDS or shock. They are associated with re-
ductions in the circulating levels of proinflammatory medi-
ators, possible improvements in gas exchange, and reduced
duration of mechanical ventilation and shock [8, 9]. How-
ever, corticosteroids increase the risk of hyperglycemia, as
well as neuropathy and myopathy related to critical illness,
and the effect of corticosteroids on the risk of infection and
survival is uncertain for critically ill patients [10–19]. Corti-
costeroids have been commonly prescribed for subsequent
influenza outbreaks such as avian influenza A(H7N9) [20].
Across studies, approximately one-third of patients with
H1N1pdm09-related critical illness have reportedly been
treated with corticosteroids. While no randomized con-
trolled trials on this topic exist, the most recent observa-
tional studies have estimated an increased risk of death
among patients receiving corticosteroids [4, 5, 7, 21–28].
Observational studies in which researchers seek to estimate
treatment effects, however, are often subject to con-
founding by indication and large imbalances in base-
line characteristics. In addition, unlike a randomized
trial in which baseline characteristics are typically defined
before randomization and exposure to the trial inter-
vention, in observational studies the time from baseline
to initiation of the intervention is variable. Furthermore,
patients’ trajectories over this time may also influence the
subsequent decision to initiate corticosteroids. Thus, to
most accurately estimate the influence of a treatment,
both baseline and time-dependent factors until initiation
of treatment should be considered. Accordingly, we ana-
lyzed a large cohort of patients with H1N1pdm09-related
critical illness to describe patterns of corticosteroid
use, identify predictors of steroid prescription, and investi-
gate clinical outcomes (adjusting for baseline and time-




We conducted a multicenter observational study of
critically ill patients infected with H1N1pdm09, the
details of which have been published previously [4, 5, 29]
and are also provided in Additional file 1: Appendixes C
and D. Local research ethics boards approved the study
and waived the need for informed consent at each partici-
pating site. All data management and statistical analyses
were conducted using SAS version 9.2 software (SAS
Institute, Cary, NC, USA).
Data collection
Data were collected from 51 sites across Canada between
16 April 2009 and 24 March 2010. Eligible patients in-
cluded all critically ill adults (age >18 years) admitted to
participating hospitals with confirmed, probable, or highly
suspected H1N1pdm09 infection [4, 5, 30, 31]. All patients
known to be receiving oral or parenteral corticosteroids
before the onset of critical illness were excluded from
analyses (Fig. 1).
Demographic variables, comorbidities, copresenting
conditions, and severity of illness by Acute Physiology
and Chronic Health Evaluation (APACHE) II score were
recorded at the onset of critical illness [4, 5, 29, 32].
Time-dependent variables used to calculate the Sequential
Organ Failure Assessment (SOFA) score were collected
Enrolled participants with confirmed or 
probable influenza A(H1N1pdm09), n=756
Enrolled participants with confirmed or 
probable influenza A(H1N1pdm09), 
n=607
Prior corticosteroid use, n=82
Missing other eligibility criterion, n=2
Missing date of ICU admission, n=2 
Fig. 1 Study participant enrollment flow diagram. ICU intensive care unit
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on days 1, 2, 3, 7, 14, and 28 [33]. Corticosteroid,
antibiotic, neuraminidase inhibitor, or other antiviral
medications were collected including type, dose, frequency,
date and time of prescription as well as any change or
cessation, as were secondary infections (blood, urine, and
respiratory culture dates), and mechanical ventilation initi-
ation and liberation, date of ICU and hospital admission,
and discharge and vital status.
The primary outcome of this study was hospital mortality
adjusting for baseline and time-dependent variables. In
Canada, live discharge from the hospital is a clinically
meaningful outcome because long-term acute care hospi-
tals that provide care to seriously ill patients immediately
after acute hospitalization generally do not exist. ICU mor-
tality is important but somewhat dependent upon clinical
discharge readiness decision-making. Secondary outcomes
included the description of corticosteroid prescription
(frequency, dose, duration, and regimen), factors associ-
ated with corticosteroid prescription, ventilator- and ICU-
free days at 28 days, and the frequency of positive bacterial
respiratory or bloodstream infections among patients who
were treated and not treated with corticosteroids [34].
Between-group analyses
Patients were described and analyzed in two groups on
the basis of receipt of corticosteroids using a two-sample
t test or the Wilcoxon rank-sum test for continuous var-
iables (reported as mean [standard deviation] or median
[interquartile range]), as appropriate, and using χ2 test
or Fisher’s exact test for discrete variables (reported as
number and proportion). Results from all multivariable
analyses are reported as odds ratios (ORs) with 95 %
confidence intervals (CIs).
Multivariable analysis adjustment: prediction of
corticosteroid use and clinical outcomes
To investigate the associations between baseline vari-
ables and corticosteroid use, a multivariable analysis was
performed. The multivariable model comprised factors
of clinical interest decided a priori and all significant co-
variates at the univariate level (p ≤ 0.2). Variables were
entered into a multivariable logistic regression model
using a forward stepwise process. We followed the
generally accepted principle of including one predictor
variable for every five to ten patients with the outcome of
interest [35]. Relevant scatterplots and multicollinearity
matrices were generated and assessed for nonlinear
relations or redundant covariates, respectively. Potential re-
dundancies were flagged where Pearson’s and Spearman’s r
were greater than or equal to 0.2. The final list of potential
or candidate variables was reconciled where necessary,
based on clinical consensus. Model integrity was examined
using standard diagnostic statistics and plots and goodness
of fit for each model for all outcomes and was examined
with the Hosmer-Lemeshow test. Two observations repre-
sented extreme points in the model and were removed
from all subsequent analyses; both of these 2 patients had
no corticosteroid exposure), leaving 605 patients). In a dis-
tinct multivariable analysis, we measured the associations
between hospital mortality and potential risk factors, in-
cluding corticosteroid exposure. We excluded 20 patients
with missing outcome data, leaving a sample size of 585
patients. Because analyses to detect differences in treat-
ment variables between survivors and nonsurvivors pose a
risk of confounding due to immortal time bias (patients
who die quickly have less ‘opportunity’ to be exposed to
certain therapies), we performed separate sensitivity ana-
lyses in which we restricted comparisons to patients who
did not die within the first 3 days after admission to the
hospital, and where we adjusted for the possibility of clus-
tering due to center effect in a hierarchical model using
generalized estimating equations [36, 37].
Propensity score adjustment
To account for residual confounding by indication of the
associations between corticosteroids and clinical out-
comes, we developed a propensity score to receive cor-
ticosteroid for each participant, employing 41 available
covariates (Tables 1 and 2), after which SOFA score and
certain laboratory values were removed as they covaried
with other variables. Body mass index was removed,
owing to a large number of missing values for height,
and pregnant patients were removed because of small
numbers and subsequent inability to match. Thus, 24
variables were included in the propensity score to receive
corticosteroid model, with all patients being assigned a
value between 0 and 1.
Next, we repeated the multivariable logistic regression,
including propensity to receive corticosteroids as a pre-
dictor variable for clinical outcomes. To further explore
the association of corticosteroids on clinical outcomes,
we performed an analysis of patients who received and
did not received corticosteroids, with each steroid-
receiving patient matched with a non–steroid-receiving
patient, based on their propensity to receive cortico-
steroids. We used greedy matching without replacement
algorithm with a caliper of 0.2 times the standard devi-
ation of the logit-transformed propensity scores [38]. To
test balance between the matched pairs based on the mea-
sured confounding variable, baseline differences were
reexamined by way of matched pair analysis. Paired t and
McNemar’s tests were used for the continuous and cat-
egorical variables, respectively, highlighting imbalance for
only 1 of the 24 covariates (SOFA day 1), and this variable
was subsequently removed. Characteristics of matched
and unmatched patients were compared. Unadjusted
survival curves were analyzed using the Kaplan-Meier
method and compared using the log-rank test.
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Time-dependent variable adjustment using marginal
structural models
Many patients are treated with steroids soon after ICU ad-
mission and data collection initiation, and do not allow in-
vestigation of the importance of time-dependent changes.
Therefore, to perform time-dependent adjustments, we
restricted analyses to patients who were alive at day 7 after
ICU admission and had not yet received steroids. We used
marginal structural models and inverse probability weight-
ing to estimate the causal effect of steroids on mortality in
the presence of time-dependent treatment and other
potential confounders before steroid exposure [39, 40].
We therefore associated all potential predictor variables,
including receipt of corticosteroids with a date (baseline
variables on day 1 and subsequent measures of physio-
logical state, occurrence of infection, receipt of ventilation,
and hemodynamic or medication treatments on the day
they were measured or administered) to establish a tem-
poral relationship with death [39, 40]. Refining marginal
structural models involves a two-step process to estimate
Table 1 Baseline characteristics of patients according to corticosteroid treatment status among critically ill patients with
H1N1pdm09
Baseline characteristicsa All patientsb (n = 607) Not treated with
corticosteroids (n = 327)
Treated with
corticosteroids (n = 280)
p Valuec
Age, years 47.4 (15.3) 46.2 (15.2) 48.8 (15.3) 0.04
Female sex, n (%) 315 (51.9) 163 (49.9) 152 (54.3) 0.28
BMI, kg/m2 32.0 (10.4) 31.8 (10.7) 32.3 (10.1) 0.62
APACHE II score 20.6 (10.0) 20.1 (9.7) 21.2 (10.3) 0.22
SOFA score, day 1 11.4 (3.7) 11.3 (3.6) 11.4 (3.8) 0.70
SOFA score (cardiovascular), day 1 1.6 (1.5) 1.6 (1.5) 1.6 (1.5) 0.91
PaO2/FiO2 ratio, day 1 155.1 (92.1) 156.3 (91.8) 153.5 (92.4) 0.73
Tidal volume (ml), day 1 514.0 (131.9) 515.8 (119.5) 513.0 (144.2) 0.84
Tidal volume per ideal body weight (ml/kg), day 1 6.2 (2.1) 6.3 (2.1) 6.1 (2.1) 0.56
Positive end-expiratory pressure, (cmH2O), day 1 10.9 (4.6) 10.7 (4.3) 11.1 (4.9) 0.39
Patients with any comorbidities (any) 543 (89.5) 280 (85.6) 263 (93.9) 0.001
Comorbidities per patient, n (%) 3.2 (2.3) 2.8 (2.2) 3.7 (2.4) <0.001
Pulmonary comorbidity, n (%) 195 (32.1) 67 (20.5) 128 (45.7) <0.001
Asthma, n (%) 124 (20.4) 42 (12.8) 82 (29.3) <0.001
COPD, n (%) 100 (16.5) 30 (9.2) 70 (25.0) <0.001
Cardiac disease, n (%) 89 (14.7) 40 (12.2) 49 (17.5) 0.07
Hypertension, n (%) 195 (32.1) 102 (31.2) 93 (33.2) 0.60
Obesityd, n (%) 145 (23.9) 74 (22.6) 71 (25.4) 0.43
Diabetes, n (%) 155 (25.7) 80 (24.5) 75 (26.8) 0.51
Immune suppressione, n (%) 35 (5.8) 10 (3.1) 25 (8.9) 0.002
Chronic renal insufficiencyf, n (%) 53 (8.9) 32 (9.8) 21 (7.5) 0.32
Dialysis dependence, n (%) 14 (2.3) 11 (3.4) 3 (1.1) 0.06
Autoimmune disease, n (%) 10 (1.7) 2 (0.6) 8 (2.9) 0.03
Cirrhosis, n (%) 26 (4.3) 14 (4.3) 12 (4.3) 0.99
Bacterial coinfection at admission, n (%) 205 (33.9) 118 (36.1) 87 (31.1) 0.19
Septic shock at admissiong, n (%) 74 (12.3) 33 (10.1) 41 (14.6) 0.09
Pregnant or postpartumh, n (%) 30 (906) 24 (14.7) 6 (4.0) 0.001
APACHE Acute Physiology and Chronic Health Evaluation, BMI body mass index, SOFA Sequential Organ Failure Assessment, COPD chronic obstructive pulmonary
disease, day 1 first day in intensive care unit, FiO2 fraction of inspired oxygen, PaO2 partial pressure of oxygen in arterial blood;
aMean (standard deviation) unless otherwise specified
bDenominators may vary for each category
cp Value reflects comparison between patients treated and not treated with corticosteroids
dObesity is defined as BMI >30 kg/m2
eImmune suppression; encompasses chemotherapy for malignancy, diagnosis of HIV/AIDS, and other immunosuppression
fChronic renal insufficiency, defined as creatinine >1.5× normal
gSeptic shock at admission as determined by the patient’s physician
hFemale subset
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weights. In step 1, we calculated stabilized weights using lo-
gistic regression models for the probability that each subject
received his or her own treatment, being censored on day k
of ICU stay, based on the previous treatment, baseline char-
acteristics, and time-dependent covariates (Additional file
1: Appendix B). In the second step, we used a weighted lo-
gistic regression model (using the weights derived in step 1)
(Additional file 2) to create generalized estimating equa-
tions to take into account the repeated measures nature of
the data. We modeled the time-dependent intercept using
restricted cubic splines with five knots for days since ICU
admission [39, 40]. We modeled the probability of receiving
steroid treatment with the assumption that once the pa-
tients were started on steroids they remained on the treat-
ment (to approximate a randomized control trial where all
events subsequent to receiving the allocated treatment are
analyzed within that treatment group).
Results
Characteristics of patients receiving corticosteroids or not
From 756 total patients, 607 adults with H1N1pdm09-
related critical illness from 47 of 51 participating Canadian
hospitals met the eligibility criteria for this study (Fig. 1).
Their mean age was 47.4 (standard deviation, 15.3) years,
and 51.9 % were female. The mean number of comorbidi-
ties per patient was 3.2 (±2.3), with the most common be-
ing hypertension, pulmonary disease, diabetes, and obesity
(Table 1). Mean APACHE II score was 20.6 (±10.0) and
mean SOFA score was 11.4 (±3.7) at the onset of critical
illness. Approximately 90 % of patients received mechanical
ventilation, and 98 (16.1 %) patients received rescue oxy-
genation therapies: high-frequency oscillatory ventilation,
inhaled nitric oxide, prone positioning, or extracor-
poreal membrane oxygenation (Table 2). Among all
patients, 46.1 % were treated with corticosteroids,
92.9 % of patients received neuraminidase inhibitors,
96.9 % received antibiotics, and 55.0 % received vaso-
pressors (Tables 2 and 3).
There were substantial differences in baseline charac-
teristics between patients who received corticosteroids
and those who did not. Patients who received corticoste-
roids were older, had more comorbidities, and were
more likely to have asthma, chronic obstructive pulmon-
ary disease (COPD), and other pulmonary, immunosup-
pressive, or autoimmune conditions, but they were less
likely to be pregnant (Table 1). Patients treated with cor-
ticosteroids were also more likely to receive mechanical
ventilation, rescue oxygenation therapies, and neuramin-
idase inhibitors (Table 2).
Corticosteroid use
The most commonly administered corticosteroids were
prednisone, methylprednisolone, and hydrocortisone
(Table 3). The median number of days of steroid of treat-
ment was 7 (interquartile range 4, 13), and the median dose
was 227 (154, 443) mg of hydrocortisone equivalents. Corti-
costeroids were started a median of 0 (0, 3) days from the
onset of critical illness and 1 (0, 3) day from the initiation
of mechanical ventilation. Median ratio of partial pressure
of oxygen in arterial blood to fraction of inspired oxygen
before corticosteroid administration was 140 (91, 220)
cmH2O, and median positive end-expiratory pressure was
10 (8, 14) cmH2O. Independent factors associated with
use of corticosteroids included preexisting pulmonary




corticosteroids (n = 327)
Treated with
corticosteroids (n = 280)
p Value
Mechanical ventilation, day 1 392 (66.2) 212 (67.5) 180 (64.8) 0.48
Mechanical ventilation, any 535 (89.2) 275 (85.4) 260 (93.5) 0.001
Rescue oxygenation strategy, any 98 (16.1) 39 (11.9) 59 (21.1) 0.002
ECMO 18 (3.0) 10 (3.1) 8 (2.9) 0.88
HFOV 61 (10.1) 27 (8.3) 34 (12.1) 0.11
Nitric oxide 52 (8.6) 21 (6.4) 31 (11.1) 0.04
Prone ventilation 11 (1.8) 3 (0.9) 8 (2.9) 0.07
Antibiotic treatment, day 1 382 (63.9) 199 (60.9) 183 (65.4) 0.25
Antibiotic treatment, any 588 (96.9) 317 (96.9) 271 (96.8) 0.91
Neuraminidase inhibitor treatment, day 1 316 (52.1) 166 (50.8) 150 (53.6) 0.49
Neuraminidase inhibitor treatment, any 564 (92.9) 294 (89.9) 270 (96.4) 0.002
Vasopressor treatment, day 1 251 (41.4) 131 (40.1) 120 (42.9) 0.49
Vasopressor treatment, any 334 (55.0) 171 (52.3) 163 (58.2) 0.14
ECMO extracorporeal membrane oxygenation; HFOV high-frequency oscillation ventilation; Day 1 first day in intensive care unit
Data are presented as number (%). Some patients received more than 1 rescue strategy.
aDenominators may vary for each category
Delaney et al. Critical Care  (2016) 20:75 Page 5 of 11
comorbidities, preexisting immunodeficiency, and septic
shock at admission to ICU (Table 4). We did not find
evidence of significant between-center differences.
Outcomes
In unadjusted analyses, patients receiving corticosteroids
had higher hospital mortality and fewer ventilator-free
and ICU-free days at 28 days, but no significant difference
in nosocomial (bloodstream and respiratory) infections
(Additional file 1: Appendix Table 5A). Both APACHE II
score (OR 1.07, 95 % CI 1.04–1.10) and corticosteroid
use (OR 1.85, 95 % CI 1.12–3.04) were associated
with hospital mortality in multivariable logistic regres-
sion (Table 5) (p = 0.70, Hosmer-Lemeshow test).
Adjusting for the likelihood of receiving corticoste-
roids by inclusion of a propensity score (Table 6 and
Additional file 1: Appendix Tables 6A, 6B, 6C) yielded a
similar association of corticosteroid treatment with hospital
mortality (OR 1.71, 95 % CI 1.05–2.78) and ventilator-free
and ICU-free days. However, after matching each pa-
tient who received corticosteroids with a patient of
similar propensity score but who did not receive
Table 4 Predictors of corticosteroid administration among critically ill patients with H1N1pdm09
Corticosteroid treatment
Characteristics and cointerventions Univariable analysis, OR (95 % CI) p Value Multivariable analysis, OR (95 % CI) p Value
Age (per 1-year increase) 1.01 (1.00, 1.02) 0.04 1.06 (0.99, 1.02) 0.41
Female sex 1.18 (0.86, 1.63) 0.31 1.33 (0.92, 1.92) 0.13
APACHE II score (per 1-point increase) 1.01 (0.99, 1.03) 0.21 1.01 (0.99, 1.03) 0.37
Number of comorbidities per patient (per 1 increase) 1.17 (1.09, 1.26) <0.001 1.04 (0.93, 1.15) 0.51
Pulmonary comorbidity 3.24 (2.27, 4.63) <0.001 3.82 (2.48, 5.87) <0.001
Cardiac disease 1.51 (0.96, 2.38) 0.07 1.00 (0.55, 1.81) 0.99
Immune suppressiona 3.09 (1.46, 6.54) 0.003 3.58 (1.59, 8.06) 0.002
Septic shock at admissionb 1.52 (0.93, 2.48) 0.09 2.20 (1.25, 3.88) 0.006
Bacterial coinfection at admission 0.80 (0.57, 1.13) 0.19 0.71 (0.48, 1.05) 0.09
APACHE Acute Physiology and Chronic Health Evaluation, CI confidence interval, OR odds ratio
aImmune suppression encompasses chemotherapy for malignancy, diagnosis of HIV/AIDS, and other immunosuppression
bSeptic shock at admission, as determined by the patient’s physician
Table 3 Description of corticosteroid use among critically ill patients with H1N1pdm09
Medication variable Median (q1, q3) or n (%)a
Corticosteroid treatment, n (%) 280 (46.1)






Duration of corticosteroids, days 7.0 (4.0, 13.0)
Dose, hydrocortisone equivalents per dayb (mg) 227 (154, 443)
Dose, hydrocortisone equivalents per day (mg/kg) 3.1 (1.7, 5.8)
Duration between onset of critical illness and corticosteroid initiation, days 0.0 (0.0, 3.0)
Duration between hospital admission and corticosteroid initiation, days 2.0 (1.0, 8.0)
Duration between onset of ventilation and corticosteroid initiation, days 1.0 (0.0, 3.0)
PaO2/FiO2 before corticosteroid administration
c (cmH2O) 140 (91, 220)
Positive End-Expiratory Pressure before corticosteroid administrationc (cmH2O) 10.0 (8.0, 14.0)
SOFA cardiovascular score before corticosteroid administration 2.0 (0.0, 3.0)
SOFA Sequential Organ Failure Assessment (SOFA score of 2 indicates patient receiving dopamine ≤5 μg/kg/minute or dobutamine any dose) [33], FiO2 fraction of
inspired oxygen, PaO2 partial pressure of oxygen in arterial blood
aDenominators may vary for each category
bhttp://www.medcalc.com/steroid.html
cPaO2/FiO2 ratio and positive end-expiratory pressure were recorded only on days 1, 3, 7, 14, and 28
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corticosteroids, there was no longer a significant asso-
ciation between corticosteroid treatment and hospital
mortality (OR 1.52, 95 % CI 0.90–2.58) (Table 6). In
addition, when we used a marginal structural model
to examine the association of baseline and time-
dependent variables over the first week of ICU admis-
sion until discharge from ICU on hospital mortality
(Table 7; Additional file 1: Appendix B), only APA-
CHE II score was an independent predictor of death; re-
ceipt of corticosteroids was not (OR 0.96, 95 % CI 0.28–
3.28) (goodness-of-fit) (Additional file 1: Appendix B).
In a sensitivity analysis using 4 days instead of 7, our
findings were similar (OR 0.84, 95 % CI 0.26–2.64) (Add-
itional file 1: Appendix Table 7A).
Discussion
To our knowledge, this is the largest observational study
of H1N1pdm09-related critical illness to investigate the
association of corticosteroid prescription on clinical out-
comes. Using multiple methods to adjust for baseline
differences between patients receiving and not receiving
corticosteroids, we estimated a substantial and signifi-
cant association between corticosteroids and increased
mortality. However, adjusting for both baseline and
time-dependent differences across the course of critical
illness did not support an association between cortico-
steroid use and mortality.
Despite conflicting prior evidence of efficacy associ-
ated with corticosteroid use in critical illness, we found
that nearly half of all patients with H1N1pdm09-related
critical illness received this therapy. Most patients re-
ceiving corticosteroids in this study had moderate to se-
vere ARDS. The frequency of prescription and median
daily corticosteroid dose were similar to the experience
reported in other series from Europe and Asia [20, 24].
We found that pulmonary disease, immune suppression,
bacterial coinfection and septic shock at admission were
independently associated with subsequent corticosteroid
administration. These findings support the notion that
COPD, asthma, and septic shock are other potential in-
dications for corticosteroid use [41–44]. While there was
substantial variability in prescribing practice at the pa-
tient level, we did not find substantial between-center
differences, indicating that the majority of variability
likely rests at the provider level.
Researchers in numerous observational studies have
attempted to estimate the effect of corticosteroids upon
clinical outcomes. In two recent methodologically rigor-
ous studies, investigators similarly examined the associ-
ation of corticosteroids and survival for patients with
H1N1pdm09-related critical illness [20, 24]. These studies
used a combination of multivariable logistic regression
and propensity score matching to adjust for baseline
differences, including severity of illness, between patients
receiving and not receiving corticosteroids. One study
Table 5 Predictors of in-hospital mortality among critically ill patients with H1N1pdm09
In-hospital mortality
Clinical characteristics and cointerventions Univariable analysis, OR (95 % CI) p Value Multivariable analysis, OR (95 % CI) p Value
Age (1-year increase) 1.02 (1.01–1.04) 0.002 1.02 (1.00–1.03) 0.15
Female sex 0.94 (0.61–1.38) 0.77 0.92 (0.56–1.50) 0.73
Corticosteroid 1.82 (1.21–2.74) 0.004 1.85 (1.12–3.04) 0.02
APACHE II score (1-point increase) 1.07 (1.05–1.11) <0.001 1.07 (1.04–1.10) <0.001
PaO2/FiO2 ratio (cmH2O), day 1 1.00 (0.99–1.00) 0.004 0.99 (0.99–1.00) 0.06
Asthma 0.64 (0.37–1.11) 0.12 0.64 (0.33–1.26) 0.20
Autoimmune disease 3.21 (0.85–12.13) 0.09 3.02 (0.75–12.20) 0.12
Bacterial coinfection at admission 1.45 (0.96–2.20) 0.08 1.20 (0.72–1.98) 0.48
APACHE Acute Physiology and Chronic Health Evaluation; Day 1 first day in intensive care unit, OR odds ratio, CI confidence interval, FiO2 fraction of inspired
oxygen, PaO2 partial pressure of oxygen in arterial blood
Table 6 Outcomes of critically ill patients with H1N1pdm09 using various adjustment methodologies
Analysis Odds ratio (95 % confidence interval) p Value
Crude unadjusted analysis 1.82 (1.21–2.74) 0.004
Multivariate logistic regression analysis 1.85 (1.12–3.04) 0.02
Multivariate logistic regression analysis adjusted for propensity score to receive corticosteroids 1.71 (1.05–2.78) 0.03
Treatment groups matched on propensity to receive corticosteroids 1.52 (0.90–2.58) 0.12
Marginal structural model adjusting for baseline and time-dependent between-group differences
over the first week of ICU admission until discharge or death
0.96 (0.28–3.28) 0.95
ICU intensive care unit
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considered steroids as a time-dependent (early vs late ad-
ministration) variable to mitigate immortal time bias that
arises from the requirement for patients to survive
long enough to receive corticosteroids, possibly lead-
ing to an overestimation of a positive treatment ef-
fect. These studies also considered changes in severity
of illness over the first 72 h of admission to the ICU
(such that deteriorating patients may be more likely
to be prescribed corticosteroids, possibly leading to
an overestimation of an adverse treatment effect) [20].
However, a multitude of other factors that may change
daily in critically ill patients (e.g., alveolar gas exchange,
ventilator requirements, hemodynamics, infectious status,
and initiation of other medications such as antibiotics or
neuraminidase inhibitors) may also influence the decision
to prescribe corticosteroids and were not accounted for in
the previous studies.
We hypothesized that the association between cortico-
steroids and mortality in other studies might be due to
the inability of multivariable analyses and propensity
scores to adjust for unmeasured patient characteristics,
confounding by indication, immortal time bias, and
postbaseline time-dependent patient differences that in-
fluence the decision to prescribe corticosteroids [45].
Unobserved factors that affect assignment to treatment
cannot be accounted for in matching procedures focused
on variables at admission to ICU [45, 46]. Propensity
matching ideally requires large samples with substantial
overlap between treatment and control groups. Any hid-
den bias due to latent variables may remain after match-
ing because the procedure controls only for observed
variables and typically not for time-dependent between-
group differences. Time-dependent differences are un-
commonly accounted for but may have substantial influ-
ences on the subsequent decision to initiate treatment
and on clinical outcomes. Marginal structural models es-
timate the causal effect of a time-dependent exposure on
outcome in the presence of baseline covariates and
time-dependent confounders and represent one method
to account for time-dependent confounders [39, 40, 47].
When we applied such a model among a greater number
of patients, using changes in such variables over the
course of the first week in the ICU until discharge or
death, we found no independent association of steroids
with in-hospital mortality. These findings are in accord-
ance with findings derived from some randomized con-
trolled trials, such as a finding of no effect of early steroid
use on mortality among patients with ARDS [18].
Our study has a number of strengths, including multi-
center representation from all regions of Canada, a rela-
tively large sample size, a priori definitions, data collection
by trained research coordinators at each center, and con-
sideration of baseline and time-dependent differences in
the estimation of treatment effect. Furthermore, to address
the possibility of unmeasured confounders, we used multi-
variable analyses employing propensity scores and case
matching and adjustment for in-ICU, time-dependent,
between-group differences. While we believe that these
analytic approaches are incrementally valuable for estimat-
ing treatment effects from observational studies in a field
where randomized trials are not yet forthcoming, it is un-
likely that we have fully adjusted for all such differences.
Without a demonstrable benefit on survival, clini-
cians must consider other side effects of corticoste-
roids when contemplating corticosteroid prescription
for patients with pandemic influenza. Multiple obser-
vational studies and controlled trials have demon-
strated increased rates of neuromyopathy, impaired
glycemic control, and the possibility of increased num-
bers of infections and/or the need for concomitant active in-
fection surveillance, all of which may impair recovery from
critical illness and are not well documented in most studies
and trials of critically ill patients [15].
Conclusions
Corticosteroids were commonly prescribed for
H1N1pdm09-related critical illness. Adjusting for only
baseline between-group differences suggested a significant
increased risk of death associated with corticosteroids.
However, after adjusting for time-dependent differences, we
found no significant association between corticosteroids
and mortality. Importantly, we have not found evi-
dence to support the frequent use of corticosteroids
among patients with H1N1pdm09-related critical illness
in the absence of other evidence-based indications
Table 7 Predictors of in-hospital mortality using adjustment for
baseline and time-dependent between-group differences over
the first week of ICU admission and until discharge from ICU
among critically ill patients with H1N1pdm09
Variable Rate ratio (95 % CI) p Value
Corticosteroid use 0.96 (0.28–3.28) 0.95
APACHE II score (1-point increase) 1.07 (1.01–1.13) 0.02
SOFA score, day 1 (1-point increase) 0.97 (0.87–1.09) 0.63
Age (1-year increase) 1.00 (0.97–1.03) 0.87
Female sex 1.53 (0.65–3.83) 0.32
Asthma (yes vs no) 0.97 (0.27–3.52) 0.96
Autoimmune disease (yes vs no) 1.92 (0.54–6.81) 0.31
APACHE Acute Physiology and Chronic Health Evaluation, SOFA Sequential
Organ Failure Assessment, CI confidence interval
In the final model (n = 286), we considered the following baseline variables
upon examination of the predictors of outcome from other analyses
(univariate, multivariate, and propensity matching) and accounting for overly
correlated pairs of variables, including admission bacterial coinfection, SOFA
score, APACHE II score, age, sex, asthma, autoimmune disease; and the
following time-dependent variables SOFA (previous day), worsening ventilation
(previous day or 2 prior days), positive blood or respiratory culture (previous
day or 2 prior days), antibiotics started (previous day), and neuraminidase
started (previous day).
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[15, 18]. Our findings provide more valid estimates of
the influence of corticosteroids on outcomes for patients
with influenza-related critical illness, add incremental
information upon which clinicians can base clinical and
research decision-making, and underscore the inherent
challenges in estimating treatment effects on the basis of
observational data.
Key messages
 While observational studies have reported significant
corticosteroid-associated mortality, corticosteroids
have remained a common treatment in influenza-
related critical illness.
 Among 607 patients with H1N1pdm09-related
critical illness from 51 Canadian ICUs,
corticosteroids were administered to 46.1 %.
 Compared with patients who did not receive
corticosteroids, patients who received
corticosteroids had higher hospital crude mortality;
however, the odds ratio association between
corticosteroid use and hospital mortality decreased
from 1.85 with multivariate logistic regression, to
1.71 after adjustment for propensity score to receive
corticosteroids, to 1.52 after case matching on
propensity score, and to 0.96 using marginal
structural modeling to adjust for time-dependent
between-group differences.
 These findings highlight the challenges and importance
in adjusting for baseline and time-dependent
confounders when estimating clinical effects of
treatments using observational studies.
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